SKVI — SKINVISIBLE, INC.

OTC · Health Care · Pharmaceuticals · CIK 1085277 ·
Last close
$0.17
Market Cap
$924.6K
52W High
$0.40
52W Low
$0.16
ADV30
625
Next earnings
Skinvisible, Inc. focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic arenas. Its flagship product, Invisicare, is a patented polymer delivery system technology that enhances the delivery of active ingredients for topically applied skin care products. The company also offers non-dermatological formulations for women's health, pain management, and other markets. In addition, it engages in the development and licensing of topical prescription and over-the-counter products, as well as the co-development of formulations for pharmaceutical clients. Further, the company provides solutions to pharmaceutical companies by reformulating products coming off patent with a new Invisicare patent, and new product benefits and line extensions. It has a licensing and collaboration agreement with Ovation Science for the use of Invisicare technology with cannabinoids for topical/transdermal products, including new formulations with THC-V targeting obesity and metabolic health. The company was formerly known as Microbial Solutions, Inc. and changed its name to Skinvisible, Inc. in February 1999. Skinvisible, Inc. was incorporated in 1998 and is based in Las Vegas, Nevada.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 5,000 5,000 -125,938 -267,184 119,419 1,798 10,649,384
Dec 2025 5,000 5,000 -114,169 -258,357 127,567 2,620 10,390,348
Sep 2025 5,000 5,000 -106,057 -250,245 133,623 645 10,138,047
Jun 2025 5,000 5,000 -136,237 -274,427 143,375 120 9,897,554

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-38,410
Investing CF
$1
Financing CF
$34,780
CapEx
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.21
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-41,010,176
Inventory
Receivables
$22,592
ST Investments
EBIT TTM
$-491,785
Pretax Income TTM
$-1,064,034
Interest Exp TTM
$572,249
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$20,000
EBITDA
$-462,095
Free Cash Flow
$327,301
Enterprise Value
$6,718,821
Total Cash
$1,798
Total Debt
$5,796,022
Shares Out
5,403,843
Trailing EPS
$-0.20
Book Value
$-1.90
ROE
ROA
-224.2%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 20,000 -496,315 -1,064,034 127,567 10,390,348 -38,410
Dec 2024 20,000 -589,589 -565,654 158,217 9,381,744 -69,834
Dec 2023 20,000 -490,375 -2,382,440 162,869 9,185,912 -77,157
Dec 2022 279,296 -238,432 -1,224,887 246,793 6,887,396 45,170

Peers — same industry

TickerNameMarket CapLastDaily %
EVFM Evofem Biosciences, Inc. $874.7K $0.01
PTIX Protagenic Therapeutics, Inc.\new $842.5K $0.47
ATXI AVENUE THERAPEUTICS, INC. $757.8K $0.23
PRFX PRF Technologies Ltd. $1.16M $1.34
OWPC One World Products, Inc. $720.7K $0.01

News headlines (Yahoo Finance, 1h cache)

Ovation Science and Skinvisible Pharmaceuticals Enhance Their Strategic Partnership in the Obesity Market with Innovative Cannabinoid Delivery Technology with New Developments and Patent Protection
2025-09-18 09:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.